Chordia Therapeutics (TSE:190A) Scaled Net Operating Assets: -0.05 (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
11 GF Score
Price 円77.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics Scaled Net Operating Assets?

Chordia Therapeutics TSE:190A -2.53% 11 Scaled Net Operating Assets is -0.05 as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Chordia Therapeutics's operating assets for the quarter that ended in Feb. 2026 was 円64.50 Mil. Chordia Therapeutics's operating liabilities for the quarter that ended in Feb. 2026 was 円197.24 Mil. Chordia Therapeutics's Total Assets for the quarter that ended in Aug. 2025 was 円2,681.35 Mil. Therefore, Chordia Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Feb. 2026 was -0.05.

Chordia Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics Scaled Net Operating Assets Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Scaled Net Operating Assets
0.03 0.01 -0.07 -0.03 -0.02

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
Scaled Net Operating Assets Get a 7-Day Free Trial 0.00 0.00 -0.01 -0.03 -0.05

TSE:190A vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Chordia Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chordia Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Chordia Therapeutics's Scaled Net Operating Assets falls into.


TSE:190A
11GF Score
Chordia Therapeutics Inc TSE:190A
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Chordia Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Aug. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Aug. 2025 )
=(Operating Assets (A: Aug. 2025 )-Operating Liabilities (A: Aug. 2025 ))/Total Assets (A: Aug. 2024 )
=(132.394-244.339)/4632.37
=-0.02

where

Operating Assets(A: Aug. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2681.349 - 2548.955
=132.394

Operating Liabilities(A: Aug. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=244.339 - 0 - 0
=244.339

Chordia Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Feb. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Feb. 2026 )
=(Operating Assets (Q: Feb. 2026 )-Operating Liabilities (Q: Feb. 2026 ))/Total Assets (Q: Aug. 2025 )
=(64.504-197.24)/2681.349
=-0.05

where

Operating Assets(Q: Feb. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2512.264 - 2447.76
=64.504

Operating Liabilities(Q: Feb. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=197.24 - 0 - 0
=197.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.05 mean?
Chordia Therapeutics (TSE:190A) has a Scaled Net Operating Assets of -0.05 as of Feb. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Chordia Therapeutics and its competitors.
Is Chordia Therapeutics' Scaled Net Operating Assets too high?
Chordia Therapeutics' current Scaled Net Operating Assets is -0.05. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Scaled Net Operating Assets compare to VRTX and REGN?
Chordia Therapeutics' Scaled Net Operating Assets of -0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current Scaled Net Operating Assets is -0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Scaled Net Operating Assets of -0.05. The current Scaled Net Operating Assets is -0.05. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Scaled Net Operating Assets is -0.05 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score

Get the complete analysis for TSE:190A

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price